QCRI Seminar Series - Frontiers in Cancer Research Wednesday, April 06, 2022 The book “Clinical Trials” by Daniel Schwartz, Robert Flamant and Joseph Lellouch, which described in full detail their distinction between pragmatic and explanatory clinical trials, was published in English in 1980, the year I became the NCIC CTG (now CCTG) director. Their ideas strongly influenced me and my colleagues thinking about how our trials should be designed and conducted. In fact, we published an argument that all cancer cooperative group trials should “be designed so that, when complete, their results at least provide a meaningful answer to a therapeutic question,”1 i.e., have a pragmatic intent. Now forty years later the meaning of what constitutes a pragmatic clinical trial has changed enormously, so that a minority of current trials are considered pragmatic. This presentation will describe how this change came about and consider its implications for understanding the relevance of trial results to clinical practice. April 4th, 2022 | Pragmatic Clinical Trials – Living the evolution of a concept - Joseph L. Pater, MD, MSc, FRCP(C) Learn more about QCRI: https://qcri.queensu.ca/ QCRI Seminar Series - https://qcri.queensu.ca/about-us/semi...
